Chiglitazar sodium combined with semaglutide for young and middle-aged overweight/obese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Xie Ping

PDF(937 KB)
Modern Medicine Journal of China ›› 2025, Vol. 27 ›› Issue (12) : 89-93. DOI: 10.3969/j.issn.1672-9463.2025.12.015

Chiglitazar sodium combined with semaglutide for young and middle-aged overweight/obese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 27(12): 89-93 https://doi.org/10.3969/j.issn.1672-9463.2025.12.015

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(937 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉